SCHEMBL6868936

SCHEMBL6868936

CC(C)C[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)CCc1ccc(-c2ccc(-c3ccccc3)cc2)cc1)C(N)=O

nearest known ligand 0.62

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 7/20 0.62
MMP8 P22894 6/20 0.62
MMP12 P39900 6/20 0.62
MMP13 P45452 5/20 0.62
MMP3 P08254 6/20 0.57
MMP10 P09238 4/20 0.57
MMP9 P14780 3/20 0.57
MMP14 P50281 2/20 0.57
ERAP2 Q6P179 3/20 0.52
ERAP1 Q9NZ08 3/20 0.52
LNPEP Q9UIQ6 3/20 0.52
PTPN1 P18031 6/20 0.49
KISS1R Q969F8 1/20 0.48
MME P08473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14122328 1.00 MMP2 (0.62) MMP2MMP8MMP12MMP13MMP3
SCHEMBL14232807 1.00 MMP2 (0.62) MMP2MMP8MMP12MMP13MMP3
SCHEMBL14122732 1.00 MMP2 (0.62) MMP2MMP8MMP12MMP13MMP3
SCHEMBL6867825 1.00 MMP2 (0.62) MMP2MMP8MMP12MMP13MMP3
SCHEMBL14122147 0.96 MMP2 (0.65) MMP2MMP8MMP12MMP13MMP3
SCHEMBL6869217 0.96 MMP2 (0.65) MMP2MMP8MMP12MMP13MMP3
SCHEMBL14232887 0.96 MMP2 (0.65) MMP2MMP8MMP12MMP13MMP3
SCHEMBL14122841 0.91 MMP12 (0.72) MMP2MMP8MMP12MMP13MMP3
SCHEMBL19111742 0.91 MMP12 (0.72) MMP2MMP8MMP12MMP13MMP3
SCHEMBL6868541 0.91 MMP12 (0.72) MMP2MMP8MMP12MMP13MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2470514-B1 PSEUDO-DIPEPTIDES AS MMP INHIBITORS COMMISSARIAT L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2017-07-12 EP disclosed
US-20120309674-A1 PSEUDODIPEPTIDES AS MMP INHIBITORS COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENE ALT (FR) 2012-12-06 US disclosed
US-20120309674-A1 PSEUDODIPEPTIDES AS MMP INHIBITORS COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENE ALT (FR) 2012-12-06 US disclosed
WO-2011023864-A1 PSEUDODIPEPTIDES AS MMP INHIBITORS COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2011-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309674-A1 PSEUDODIPEPTIDES AS MMP INHIBITORS MMP3, MMP11, TIMP3 MMP2 16/4885MMP8 40/4885MMP12 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.